BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26
Oric Pharmaceuticals Inc ORIC
$13.16
▼ -0.15%
($-0.02)
🔥 High Short Interest
Open
$13.27
Prev Close
$13.18
Day Range
$12.94 – $13.49
52W Range
$7.23 – $14.93
Market Cap
$1.36B
Beta
1.14
EPS (TTM)
$-1.35
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-04-24 |
| Shares Out. | 103,520,000 |
| Website | oricpharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 111 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$41.5M |
| Free Cash Flow | -$112.3M |
| Total Assets | $404.7M |
| Total Liabilities | $23.4M |
| Equity | $381.3M |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Oric Pharmaceuticals Inc is a publicly traded company under the ticker symbol ORIC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-09-01)